No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS)

BACKGROUND AND OBJECTIVES: Some patients with multiple sclerosis (MS) receiving ocrelizumab (OCR) report worsening symptoms toward the end of the 6-month infusion cycle (‘wearing off’). The objective of our study was to comprehensively assess changes in symptom burden across 2 consecutive OCR infusi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kister, Ilya, Oh, Cheongeun, Douglas, Elizabeth A., Bacon, Tamar E., O'Shea, Isabella L., Parrotta, Erica H., Bouley, Andrew, Lathi, Ellen, Katz, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479935/
https://www.ncbi.nlm.nih.gov/pubmed/37674871
http://dx.doi.org/10.1212/CPJ.0000000000200185

Ejemplares similares

Ejemplares similares